225 related articles for article (PubMed ID: 17403090)
21. Efficacy and safety of von Willebrand factor concentrate almost devoid of factor VIII (Wilfactin
Gouider E; Klukowska A; Maes P; Platokouki H; Pujol S; Henriet C; Bridey F; Goudemand J
Blood Transfus; 2023 Jan; 21(1):83-92. PubMed ID: 35543677
[TBL] [Abstract][Full Text] [Related]
22. In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease.
Ver Elst KM; van Vliet HD; Kappers-Klunne MC; Leebeek FW
Thromb Haemost; 2004 Jul; 92(1):67-74. PubMed ID: 15213847
[TBL] [Abstract][Full Text] [Related]
23. Clinical Efficacy and Safety of Fanhdi
Jiménez-Yuste V; Alvarez-Román MT; Palomo Bravo Á; Galmes BJ; Nieto Hernández MDM; Benítez Hidalgo O; Marzo Alonso C; Pérez González NF; Coll J; Núñez R; Carrasco M; García Candel F; Gonzalez-Porras JR; Hernández García C; Varó Castro MJ; Mir R
Clin Appl Thromb Hemost; 2022; 28():10760296221074348. PubMed ID: 35108125
[TBL] [Abstract][Full Text] [Related]
24. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
Federici AB
Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
[TBL] [Abstract][Full Text] [Related]
25. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
26. Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage.
Franchini M
Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s33-8. PubMed ID: 19105508
[TBL] [Abstract][Full Text] [Related]
27. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease.
Castaman G; Coppola A; Zanon E; Boeri E; Musso M; Siragusa S; Federici AB; Mancuso G; Barillari G; Biasoli C; Feola G; Franchini M; Moratelli S; Gamba G; Schinco P; Valdrè L; Dragani A; Mazzucconi G; Tagliaferri A; Morfini M
Haemophilia; 2013 Jan; 19(1):82-8. PubMed ID: 22957493
[TBL] [Abstract][Full Text] [Related]
29. Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.
Peyvandi F; Mamaev A; Wang JD; Stasyshyn O; Timofeeva M; Curry N; Cid AR; Yee TT; Kavakli K; Castaman G; Sytkowski A
J Thromb Haemost; 2019 Jan; 17(1):52-62. PubMed ID: 30362288
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy.
Gill JC; Ewenstein BM; Thompson AR; Mueller-Velten G; Schwartz BA;
Haemophilia; 2003 Nov; 9(6):688-95. PubMed ID: 14750934
[TBL] [Abstract][Full Text] [Related]
31. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial.
Mannucci PM; Tenconi PM; Castaman G; Rodeghiero F
Blood; 1992 Jun; 79(12):3130-7. PubMed ID: 1596562
[TBL] [Abstract][Full Text] [Related]
32. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.
Peyvandi F; Castaman G; Gresele P; De Cristofaro R; Schinco P; Bertomoro A; Morfini M; Gamba G; Barillari G; Jiménez-Yuste V; Königs C; Iorio A; Federici AB
Blood Transfus; 2019 Sep; 17(5):391-398. PubMed ID: 30747707
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of Wilate in paediatric VWD patients under 6 years of age - results of a prospective multicentre clinical study including recovery information.
Nowak-Göttl U; Krümpel A; Russo A; Jansen M
Haemophilia; 2013 Nov; 19(6):887-92. PubMed ID: 23919249
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures.
Shortt J; Dunkley S; Rickard K; Baker R; Street A
Haemophilia; 2007 Mar; 13(2):144-8. PubMed ID: 17286766
[TBL] [Abstract][Full Text] [Related]
36. Analysis of current perioperative management with Haemate
Hazendonk HCAM; Heijdra JM; de Jager NCB; Veerman HC; Boender J; van Moort I; Mathôt RAA; Meijer K; Laros-van Gorkom BAP; Eikenboom J; Fijnvandraat K; Leebeek FWG; Cnossen MH;
Haemophilia; 2018 May; 24(3):460-470. PubMed ID: 29573506
[TBL] [Abstract][Full Text] [Related]
37. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
38. Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results.
Bello IF; Yuste VJ; Molina MQ; Navarro FH
Haemophilia; 2007 Dec; 13 Suppl 5():25-32. PubMed ID: 18078394
[TBL] [Abstract][Full Text] [Related]
39. Treatment of von Willebrand disease.
Rodeghiero F; Castaman G
Semin Hematol; 2005 Jan; 42(1):29-35. PubMed ID: 15662613
[TBL] [Abstract][Full Text] [Related]
40. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
Klukowska A; Windyga J; Batorova A
Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]